Your browser is no longer supported. Please, upgrade your browser.
Settings
AKBA Akebia Therapeutics, Inc. daily Stock Chart
AKBA [NASD]
Akebia Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.24 Insider Own1.50% Shs Outstand56.99M Perf Week-1.19%
Market Cap567.05M Forward P/E- EPS next Y-1.30 Insider Trans-0.12% Shs Float47.63M Perf Month-5.69%
Income-55.80M PEG- EPS next Q-0.51 Inst Own73.90% Short Float7.69% Perf Quarter1.84%
Sales203.00M P/S2.79 EPS this Y50.90% Inst Trans-0.23% Short Ratio7.13 Perf Half Y-36.14%
Book/sh4.05 P/B2.46 EPS next Y30.90% ROA-15.10% Target Price22.00 Perf Year-29.48%
Cash/sh6.90 P/C1.44 EPS next 5Y- ROE-46.80% 52W Range7.90 - 20.25 Perf YTD-33.09%
Dividend- P/FCF- EPS past 5Y-22.90% ROI-65.20% 52W High-50.86% Beta1.08
Dividend %- Quick Ratio2.90 Sales past 5Y- Gross Margin- 52W Low25.95% ATR0.49
Employees114 Current Ratio2.90 Sales Q/Q119.60% Oper. Margin-29.30% RSI (14)45.39 Volatility2.73% 5.82%
OptionableYes Debt/Eq0.00 EPS Q/Q58.10% Profit Margin-27.50% Rel Volume0.99 Prev Close10.05
ShortableYes LT Debt/Eq0.00 EarningsAug 08 AMC Payout- Avg Volume513.30K Price9.95
Recom2.00 SMA20-4.05% SMA50-2.26% SMA200-26.11% Volume509,119 Change-1.00%
Jun-06-18Reiterated H.C. Wainwright Buy $24 → $22
Dec-19-17Initiated Piper Jaffray Overweight $26
Dec-07-17Initiated BTIG Research Buy $30
Sep-15-17Initiated RBC Capital Mkts Sector Perform $17
Jul-10-17Reiterated H.C. Wainwright Buy $25 → $24
Apr-27-17Reiterated Needham Buy $14 → $18
Apr-27-17Reiterated H.C. Wainwright Buy $18 → $21
Dec-27-16Reiterated H.C. Wainwright Buy $17 → $18
Dec-20-16Reiterated JMP Securities Mkt Outperform $16 → $19
Nov-15-16Initiated Aegis Capital Buy
Sep-29-16Initiated Brean Capital Buy
Mar-16-16Reiterated Needham Buy $18 → $14
Jan-21-16Initiated Credit Suisse Neutral
Dec-15-15Reiterated Needham Buy $14 → $18
Dec-15-15Reiterated H.C. Wainwright Buy $24 → $25
Dec-07-15Initiated H.C. Wainwright Buy $24
Sep-09-15Upgrade Morgan Stanley Equal-Weight → Overweight
Aug-13-15Initiated Morgan Stanley Equal-Weight $10
Jun-22-15Initiated JMP Securities Mkt Outperform $24
May-14-15Initiated Brean Capital Buy $18
Jul-06-18 03:07PM  INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Keryx Biopharmaceuticals, Inc. to Akebia Therapeutics, Inc. is Fair to Shareholders GlobeNewswire
Jul-05-18 06:17PM  Biotech Stock Roundup: GILD's Positive CHMP Nod, Regulatory Updates & More Zacks
Jul-02-18 04:05PM  Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Jun-29-18 07:12PM  WeissLaw LLP Investigates Keryx Biopharmaceuticals Inc. PR Newswire +6.62%
09:08AM  Keryx (KERX) Inks Merger Deal With Akebia, Shares Fall Zacks
Jun-28-18 11:21AM  Here's Why Keryx Biopharmaceuticals and Akebia Therapeutics Are Plunging Today Motley Fool -9.83%
07:00AM  Akebia Therapeutics and Keryx Biopharmaceuticals to Merge, Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease Business Wire
Jun-26-18 07:51PM  Ex-Akebia employee jailed for night as insider trading trial starts Reuters
04:02PM  Ex-Akebia employee jailed for night as insider trading trial starts Reuters
Jun-11-18 07:40AM  Todays Free Research Reports Coverage on Agenus and Three More Biotech Stocks ACCESSWIRE
Jun-06-18 08:10AM  Investor Expectations to Drive Momentum within Core-Mark Holding, SSR Mining, iRhythm Technologies, Magic Software Enterprises, Jounce Therapeutics, and Akebia Therapeutics Discovering Underlying Factors of Influence GlobeNewswire +5.09%
Jun-04-18 04:05PM  Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
May-15-18 04:05PM  Akebia Therapeutics to Present at Upcoming Investor Conference Business Wire
May-09-18 05:16PM  Akebia Therapeutics: 1Q Earnings Snapshot Associated Press
May-02-18 04:05PM  Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Apr-09-18 07:50AM  Research Report Identifies Yirendai, Atlantic Capital Bancshares, Jazz Pharmaceuticals, Sina, Akebia Therapeutics, and SMART Global with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Apr-03-18 04:05PM  Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Mar-23-18 08:00AM  Akebia Therapeutics Announces Pricing of Public Offering of Common Stock Business Wire -10.19%
Mar-22-18 04:26PM  Akebia Therapeutics Announces Proposed Public Offering of Common Stock Business Wire
Mar-21-18 08:30AM  Akebia Therapeutics to Present at Upcoming Investor Conferences Business Wire
Mar-20-18 07:40AM  Blog Exposure - Chiasma to Present Design of Phase-3 Double-Blind Trial of Oral Octreotide Capsules Versus Placebo in Acromegaly Patients at ENDO 2018 ACCESSWIRE
Mar-16-18 08:30AM  New Research: Key Drivers of Growth for CNB Financial, Akebia Therapeutics, Mesoblast, 21Vianet Group, Old Line Bancshares, and BioSpecifics Technologies Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Mar-13-18 01:11PM  Edited Transcript of AKBA earnings conference call or presentation 12-Mar-18 8:30pm GMT Thomson Reuters StreetEvents -6.88%
Mar-12-18 04:29PM  Akebia Therapeutics posts 4Q profit Associated Press
04:03PM  Akebia Therapeutics Announces Fourth Quarter and Full-Year 2017 Financial Results Business Wire
01:15PM  Akebia Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-05-18 08:30AM  Akebia Therapeutics to Host Fourth Quarter and Full-Year 2017 Investor Update Call and Webcast Business Wire
Mar-02-18 04:05PM  Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Feb-12-18 07:00AM  Akebia Therapeutics Provides Update on Vadadustat Development Program Business Wire
Feb-08-18 08:00AM  Akebia Therapeutics to Present at Upcoming February Investor Conferences Business Wire
Feb-02-18 04:30PM  Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Jan-04-18 07:00AM  Akebia Therapeutics Announces Positive Top-Line Results from Phase 2 Study of Vadadustat in Japanese Patients with Anemia Associated with Dialysis-Dependent Chronic Kidney Disease Business Wire
Jan-02-18 04:05PM  Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Dec-13-17 08:44AM  Market Has Not Yet Noticed Potential in Akebia Therapeutics (AKBA); Have You? Zacks
Dec-07-17 08:46AM  Falling Earnings Estimates Signal Weakness Ahead for Aerie Pharmaceuticals (AERI) Zacks
Dec-06-17 09:07AM  The Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimetics Zacks
Dec-05-17 08:09AM  5 Top-Ranked Drug Stocks that are Broker Favorites Zacks
Dec-04-17 08:52AM  Concert Pharmaceuticals (CNCE) Soars: Stock Adds 5.7% in Session Zacks
Dec-01-17 04:05PM  Akebia Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Nov-28-17 08:36AM  GlycoMimetics (GLYC) Jumps: Stock Rises 11.9% Zacks
Nov-16-17 08:00AM  Akebia Therapeutics to Participate in Upcoming Investor Conferences Business Wire
Nov-14-17 12:25PM  Newly public Cincinnati firm names new CFO American City Business Journals -5.51%
Nov-08-17 05:33PM  Akebia Therapeutics reports 3Q loss Associated Press
04:05PM  Akebia Therapeutics Announces Third Quarter 2017 Financial Results Business Wire
Nov-07-17 12:33PM  Is Akebia Therapeutics Incs (AKBA) Liquidity As Good As Its Solvency? Simply Wall St.
Nov-03-17 04:05PM  Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Oct-27-17 11:29AM  Akebia Therapeutics, Inc. Value Analysis (NASDAQ:AKBA) : October 27, 2017 Capital Cube
Oct-26-17 08:20AM  Akebia Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : AKBA-US : October 26, 2017 Capital Cube
Oct-04-17 04:05PM  Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Sep-26-17 04:26PM  Axovant Shares Plummet On Alzheimer's Data; Genocea Gets Rocked -Biotech Movers TheStreet.com
07:00AM  Akebia Announces Positive Top-Line Results from Phase 2 Study of Vadadustat in Japanese Patients with Non-Dialysis-Dependent Chronic Kidney Disease Business Wire
Sep-22-17 05:33PM  Ex-Akebia employee suspected of insider trading re-arrested Reuters
05:27PM  Ex-Akebia employee suspected of insider trading re-arrested Reuters
Sep-08-17 08:35AM  Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Sep-07-17 01:24PM  BioMarin Presents Interim Data on BMN 250 from Phase I/II Zacks
Sep-05-17 08:42AM  Why Akebia Therapeutics (AKBA) Could Be Positioned for a Surge Zacks
08:30AM  Akebia to Present at Upcoming Investor Conferences Business Wire
Aug-23-17 07:10AM  Featured Company News - ContraVir Announces Issuance of New US Patent for Expansion of Cyclophilin Inhibitor Program ACCESSWIRE
Aug-14-17 08:27AM  Akebia Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : AKBA-US : August 14, 2017 Capital Cube
Aug-08-17 11:04PM  Akebia Therapeutics reports 2Q loss Associated Press
04:05PM  Akebia Announces Second Quarter 2017 Financial Results Business Wire
Aug-04-17 04:05PM  Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Jul-24-17 01:53PM  ETFs with exposure to Akebia Therapeutics, Inc. : July 24, 2017 Capital Cube
Jul-20-17 05:08PM  Ex-Akebia employee faces losing bail in insider trading case Reuters
Jul-14-17 12:41PM  ETFs with exposure to Akebia Therapeutics, Inc. : July 14, 2017 Capital Cube
Jul-12-17 03:09PM  Akebia Therapeutics, Inc. Value Analysis (NASDAQ:AKBA) : July 12, 2017 Capital Cube
Jul-11-17 09:15AM  Akebia Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : AKBA-US : July 11, 2017 Capital Cube
Jul-06-17 07:00AM  Akebia Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters Business Wire
Jun-29-17 09:26AM  Biotech Movers: Akebia Shares Down After Pricing Stock Offering TheStreet.com
Jun-28-17 10:46PM  Akebia Announces Pricing of Public Offering of Common Stock Business Wire
04:15PM  Akebia Therapeutics Announces Proposed Public Offering of Common Stock Business Wire
Jun-20-17 07:00AM  Akebia Therapeutics to Host Analyst and Investor Day on June 27, 2017 Business Wire
Jun-05-17 08:00AM  Akebia Prevails in Two Additional European Patent Disputes Business Wire
May-25-17 08:30AM  Akebia Therapeutics Names Rita Jain, M.D. as Chief Medical Officer Business Wire
May-24-17 07:00AM  Akebia Initiates Phase 2 FO2RWARD Study of Vadadustat in Dialysis Patients with Anemia Related to Chronic Kidney Disease Hyporesponsive to Treatment with Erythropoiesis-Stimulating Agents Business Wire
May-17-17 06:59PM  Four Stocks Moving On Both News And The Charts Forbes
08:00AM  Today's Research Reports on Stocks to Watch: Akebia Therapeutics and xG Technology Accesswire
May-16-17 12:02PM  Why Akebia Therapeutics Stock Is Skyrocketing Today Motley Fool +16.36%
09:34AM  Biotech Movers: Akebia, Editas, Novavax TheStreet.com
01:01AM  Vifor Pharma and Akebia Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval GlobeNewswire
May-15-17 04:05PM  Akebia Secures Exclusive Access to U.S. Dialysis Patients With Vifor-Fresenius Pact TheStreet.com
04:05PM  Akebia and Vifor Pharma Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval Business Wire
May-09-17 06:28PM  Akebia Therapeutics reports 1Q loss Associated Press
04:05PM  Akebia Announces First Quarter 2017 Financial Results Business Wire
May-04-17 04:05PM  Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Apr-28-17 04:34PM  Akebia Therapeutics, Inc. Value Analysis (NASDAQ:AKBA) : April 28, 2017 Capital Cube
08:20AM  Akebia Therapeutics (AKBA) Shows Strength: Stock Up 5.8% Zacks
Apr-27-17 12:05PM  4 Things To Know About Akebia's New Vadadustat Collaboration With Otsuka Pharma Benzinga +5.84%
08:33AM  Akebia Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : AKBA-US : April 27, 2017 Capital Cube
Apr-26-17 05:45PM  Why Akebia Therapeutics Shares Soared 33.4% Today Motley Fool +33.40%
10:59AM  Akebia Surges but is Still Undervalued, Making Takeover a Potential Remedy TheStreet.com
09:27AM  Biotech Movers: Akebia Soars on Expanded Partnership With Otsuka TheStreet.com
Apr-25-17 07:00PM  Akebia expands anemia drug pact with Japanese firm, lifting shares American City Business Journals
05:41PM  Akebia shares jump on expanded anemia drug deal with Otsuka MarketWatch
04:25PM  Akebia Expands Anemia Pill Partnership to Include Europe, China Rights TheStreet.com
04:05PM  Akebia and Otsuka Expand Relationship with Collaboration to Develop and Commercialise Vadadustat in Europe, China and Other Territories Business Wire
04:01PM  Akebia and Otsuka Expand Relationship with Collaboration to Develop and Commercialize Vadadustat in Europe, China and Other Territories Business Wire
Apr-07-17 07:30AM  Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Mar-29-17 04:05PM  Akebia to Present at the 16th Annual Needham Healthcare Conference Business Wire
Mar-28-17 07:00AM  Akebia Announces Publication of Phase 2a Results for Vadadustat in Patients with Anemia Related to Chronic Kidney Disease Business Wire
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with renal disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease in dialysis and non-dialysis patients. The company is also developing a HIF-based portfolio of product candidates, such as AKB-5169, a preclinical compound for the treatment of inflammatory bowel disease. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds internationally. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Butler John P.CEO and PresidentJul 11Option Exercise0.47100,00047,000510,314Jul 12 04:59 PM
Nash DuaneDirectorFeb 15Sale14.621,00014,62021,499Feb 16 04:07 PM
Dahan MichelSVP, Chief Business OfficerOct 02Sale19.641,39827,45795,826Oct 04 04:20 PM
Hadas Nicole R.SVP, General Counsel, Sec.Oct 02Sale19.897,803155,188101,804Oct 04 04:21 PM
Nash DuaneDirectorOct 02Sale19.641,18823,33222,499Oct 04 04:21 PM
Dahan MichelSVP, Chief Business OfficerSep 28Sale19.305,00096,50097,224Oct 02 04:04 PM
Dahan MichelSVP, Chief Business OfficerAug 15Sale15.005,00075,000102,224Aug 17 04:06 PM